person · Reporting owner
McDougal Lori Courtney
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ReShape Weightloss Inc.ETRM · Entity 137993 | Director | February 08, 2017 | February 10, 2017 |
| Vyome Holdings, IncRSLS · Entity 1824 | Director | July 22, 2021 | September 17, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ReShape Weightloss Inc.
Report date February 08, 2017 · Filed February 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.12 · Expires 2027-02-08 | Direct | 30,000 |
Reported balance
After 2017-02-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-02-08 · Grant · Acquired 30,000 · Balance 30,000 F3: Vests immediately as to 25% on date noted and thereafter in cumulative installments of 1/36th per month. |
| Director Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $325.50 · Expires 2025-07-31 | Direct | 23 |
Reported balance
Holding disclosure · report date 2017-02-08 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 23 F1: On December 27, 2016, EnteroMedics Inc. effected a 1-for-70 reverse stock split of its issued and outstanding shares of common stock, par value $0.01 per share, resulting in a proportional decrease in the total shares of common stock beneficially owned by the reporting person. all previously reported exercise prices, option grants and similar instruments convertible into common stock were proportionally adjusted to reflect the reverse split. F2: 25% of the shares subject to the option are exercisable immediately. The remaining 75% of the shares subject to the option shall vest in a series of thirty-six (36) successive equal monthly installments upon completion of each month beginning on August 31, 2015 and ending on July 31, 2018. |
| Director Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.50 · Expires 2026-05-04 | Direct | 42 |
Reported balance
Holding disclosure · report date 2017-02-08 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 42 F1: On December 27, 2016, EnteroMedics Inc. effected a 1-for-70 reverse stock split of its issued and outstanding shares of common stock, par value $0.01 per share, resulting in a proportional decrease in the total shares of common stock beneficially owned by the reporting person. all previously reported exercise prices, option grants and similar instruments convertible into common stock were proportionally adjusted to reflect the reverse split. F3: Vests immediately as to 25% on date noted and thereafter in cumulative installments of 1/36th per month. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2017-02-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: On December 27, 2016, EnteroMedics Inc. effected a 1-for-70 reverse stock split of its issued and outstanding shares of common stock, par value $0.01 per share, resulting in a proportional decrease in the total shares of common stock beneficially owned by the reporting person. all previously reported exercise prices, option grants and similar instruments convertible into common stock were proportionally adjusted to reflect the reverse split.
F2: 25% of the shares subject to the option are exercisable immediately. The remaining 75% of the shares subject to the option shall vest in a series of thirty-six (36) successive equal monthly installments upon completion of each month beginning on August 31, 2015 and ending on July 31, 2018.
F3: Vests immediately as to 25% on date noted and thereafter in cumulative installments of 1/36th per month.
Vyome Holdings, Inc
Report date July 22, 2021 · Filed September 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | Direct | 253,429 |
Reported balance
After 2021-07-22 transaction · row 1
1 source rowRow 1 · 2021-07-22 · Grant · Acquired 253,429 · Balance 253,429 F1: These shares will vest and be issued with respect to 241,961 shares on each of July 22, 2021 and July 22, 2022 pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares will vest and be issued with respect to 241,961 shares on each of July 22, 2021 and July 22, 2022 pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 22, 2021 Filed Sep 17, 2021 18:07 UTC | Vyome Holdings, Inc RSLS · Entity 1824 | GrantCommon Stock, $0.001 par value per share | 253,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001790300-21-000006 · primary_doc.xml · nonDerivative · entry 1 McDougal Lori Courtney · CIK 0001649837 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,429 F1 · shares: These shares will vest and be issued with respect to 241,961 shares on each of July 22, 2021 and July 22, 2022 pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:50 UTC | ReShape Weightloss Inc. ETRM · Entity 137993 | GrantDirector Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001209191-17-009595 · doc4.xml · derivative · entry 4 McDougal Lori Courtney · CIK 0001649837 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-02-08 F3 · derivative.exercise_date: Vests immediately as to 25% on date noted and thereafter in cumulative installments of 1/36th per month. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.